Up-regulation of Survivin by the E2A-HLF Chimera Is Indispensable for the Survival of t(17;19)-positive Leukemia Cells*

The E2A-HLF fusion transcription factor generated by t(17;19)(q22;p13) translocation is found in a small subset of pro-B cell acute lymphoblastic leukemias (ALLs) and promotes leukemogenesis by substituting for the antiapoptotic function of cytokines. Here we show that t(17;19)+ ALL cells express Survivin at high levels and that a dominant negative mutant of E2A-HLF suppresses Survivin expression. Forced expression of E2A-HLF in t(17;19)− leukemia cells up-regulated Survivin expression, suggesting that Survivin is a downstream target of E2A-HLF. Analysis using a counterflow centrifugal elutriator revealed that t(17;19)+ ALL cells express Survivin throughout the cell cycle. Reporter assays revealed that E2A-HLF induces survivin expression at the transcriptional level likely through indirect down-regulation of a cell cycle-dependent cis element in the promoter region. Down-regulation of Survivin function by a dominant negative mutant of Survivin or reduction of Survivin expression induced massive apoptosis throughout the cell cycle in t(17;19)+ cells mainly through caspase-independent pathways involving translocation of apoptosis-inducing factor (AIF) from mitochondria to the nucleus. AIF knockdown conferred resistance to apoptosis caused by down-regulation of Survivin function. These data indicated that reversal of AIF translocation by Survivin, which is induced by E2A-HLF throughout the cell cycle, is one of the key mechanisms in the protection of t(17;19)+ leukemia cells from apoptosis.

[1]  O. Podhajcer,et al.  Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase‐independent pathway , 2008, Journal of cellular biochemistry.

[2]  T. Inaba,et al.  Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells. , 2008, The Tohoku journal of experimental medicine.

[3]  D. Altieri.  Survivin, cancer networks and pathway-directed drug discovery , 2008, Nature Reviews Cancer.

[4]  Y. Furukawa,et al.  E2F‐6 Suppresses Growth‐Associated Apoptosis of Human Hematopoietic Progenitor Cells by Counteracting Proapoptotic Activity of E2F‐1 , 2007, Stem cells.

[5]  J. Ménissier-de murcia,et al.  Sequential Activation of Poly(ADP-Ribose) Polymerase 1, Calpains, and Bax Is Essential in Apoptosis-Inducing Factor-Mediated Programmed Necrosis , 2007, Molecular and Cellular Biology.

[6]  T. Inaba,et al.  Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19 , 2007, Leukemia.

[7]  S. Leachman,et al.  Activation of dual apoptotic pathways in human melanocytes and protection by survivin. , 2006, The Journal of investigative dermatology.

[8]  Fengzhi Li,et al.  Survivin study: An update of “What is the next wave?” , 2006, Journal of cellular physiology.

[9]  G. Kroemer,et al.  Apoptosis-inducing factor: vital and lethal. , 2006, Trends in cell biology.

[10]  S. Fukuda,et al.  Survivin, a cancer target with an emerging role in normal adult tissues , 2006, Molecular Cancer Therapeutics.

[11]  A. Schimmer.  Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice , 2004, Cancer Research.

[12]  A. Look,et al.  Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein. , 2004, Blood.

[13]  D. Grossman,et al.  Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells , 2004, Oncogene.

[14]  H. Sung,et al.  Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. , 2003, Blood.

[15]  M. Yuen,et al.  Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. , 2003, Cancer research.

[16]  Fengzhi Li.  Survivin study: What is the next wave? , 2003, Journal of cellular physiology.

[17]  C. Schamberger,et al.  Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras , 2003, Oncogene.

[18]  Michael T. McManus,et al.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference , 2003, Nature Genetics.

[19]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[20]  A. Ferrando,et al.  Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. , 2002, Cancer cell.

[21]  T. Dawson,et al.  Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor , 2002, Science.

[22]  G. Krissansen,et al.  Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. , 2001, Journal of the National Cancer Institute.

[23]  A. Look,et al.  SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. , 1999, Molecular cell.

[24]  H. Horvitz,et al.  The C. elegans cell death specification gene ces-1 encodes a snail family zinc finger protein. , 1999, Molecular cell.

[25]  A. Look,et al.  Two Distinct Interleukin-3-Mediated Signal Pathways, Ras-NFIL3 (E4BP4) and Bcl-xL, Regulate the Survival of Murine Pro-B Lymphocytes , 1999, Molecular and Cellular Biology.

[26]  M. Hatano,et al.  Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[28]  C. Naeve,et al.  Two Candidate Downstream Target Genes for E2A-HLF , 1999 .

[29]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[30]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[31]  A. Look,et al.  The AD1 and AD2 Transactivation Domains of E2A Are Essential for the Antiapoptotic Activity of the Chimeric Oncoprotein E2A-HLF , 1998, Molecular and Cellular Biology.

[32]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[33]  M. Kitagawa,et al.  Polyploidization and functional maturation are two distinct processes during megakaryocytic differentiation: involvement of cyclin-dependent kinase inhibitor p21 in polyploidization. , 1997, Blood.

[34]  J L Cleveland,et al.  Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Horvitz,et al.  Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2 , 1996, Nature.

[36]  A. Look,et al.  Reversal of apoptosis by the leukaemia-associated E2A–HLF chimaeric transcription factor , 1996, Nature.

[37]  S. Hunger,et al.  Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. , 1996, Blood.

[38]  K. Arai,et al.  Suppression of apoptotic death in hematopoietic cells by signalling through the IL‐3/GM‐CSF receptors. , 1995, The EMBO journal.

[39]  T. Inaba,et al.  DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein , 1994, Molecular and cellular biology.

[40]  M. Cleary,et al.  Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. , 1992, Genes & development.

[41]  S. Raimondi,et al.  Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. , 1992, Science.